Flare Associated with LHRH-Agonist Therapy.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Reviews in urology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 16986003PMCID PMC1476081
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Views from funding agencies. Agency for Health Care Policy and Research.

  1998cited by this paper
• Luteinizing hormone‐releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low‐dose diethylstilbestrol

  1993cited by this paper
• Combination treatment in M1 prostate cancer

  1993cited by this paper
• Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.

  1990cited by this paper
• Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

  1990cited by this paper
• Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).

  1989cited by this paper
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

  1989cited by this paper
• Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.

  1989cited by this paper
• Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?

  1988cited by this paper
• Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.

  1988cited by this paper
• A Review of the Hammersmith Hospital, St. Bartholomew's Hospital, and Institute of Urology Studies of Buserelin in Advanced Prostatic Cancer

  1988cited by this paper
• Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.

  1987cited by this paper
• Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.

  1987cited by this paper
• Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.

  1986cited by this paper
• DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate.

  1985cited by this paper
• Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.

  1985cited by this paper
• COMBINED TREATMENT WITH BUSEREUN AND CYPROTERONE ACETATE IN METASTATIC PROSTATIC CARCINOMA

  1985cited by this paper
• Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.

  1985cited by this paper
• Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer.

  1984cited by this paper
• Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

  1984cited by this paper
• Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer.

  1983cited by this paper
• The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue.

  1983cited by this paper

• Changes to Patterns of Oncology Medicine Dispensing in Response to the Onset of the COVID‐19 Pandemic in Ireland: An Interrupted Time Series Analysis

  2025cites this paper
• Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy

  2025cites this paper
• Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer

  2024cites this paper
• Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis

  2024cites this paper
• Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer.

  2024cites this paper
• Design, Synthesis, Characterization, and Cytotoxicity of New Pyrazolylmethylene-2-thioxoimidazolidin-4-one Derivatives towards Androgen-Sensitive LNCaP Prostate Cancer Cells

  2024cites this paper
• The Intersection of Prostate Cancer and Hypertension: a Call to Action

  2023cites this paper
• An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer

  2023cites this paper
• Mechanistic evaluation of the initial burst release of leuprolide from spray-dried PLGA microspheres.

  2023cites this paper
• Relugolix: A Review in Advanced Prostate Cancer

  2023cites this paper
• Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety

  2022cites this paper
• Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer

  2022cites this paper
• Absence of PSA Flare With Apalutamide Administered 1 Hour in Advance With GnRH Agonists: Case Report

  2022cites this paper
• Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare

  2022cites this paper
• A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy

  2021cites this paper
• Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review

  2021cites this paper
• Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer

  2021cites this paper
• Cardiovascular Toxicities of Androgen Deprivation Therapy

  2021cites this paper
• Role of primary care in the management of prostate cancer

  2021cites this paper
• Hormonal Therapy for Prostate Cancer.

  2021cites this paper
• The role of adrenal derived androgens in castration resistant prostate cancer.

  2020cites this paper
• Entwicklung einer großen intraprostatischen Zyste nach Einsatz eines GnRH-Agonist-Implantats bei einem Rüden mit benigner Prostatahyperplasie

  2020cites this paper
• Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer

  2020cites this paper
• The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.

  2020cites this paper
• Prescription switching: Rationales and risks

  2020cites this paper
• Acute Cancer Pain Syndromes in Palliative Care Emergencies

  2019cites this paper
• Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations.

  2019cites this paper
• Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use

  2019cites this paper
• A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.

  2019cites this paper
• GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression

  2019cites this paper
• Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer

  2019cites this paper
• Disrupting Androgen Receptor Transactivation Domains to Identify Lead Compounds with Potential to be Optimized and Developed into Prostate Cancer Therapeutics

  2019influential citation
• Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor

  2019cites this paper
• Cardiovascular risk with androgen deprivation therapy

  2019cites this paper
• Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden

  2019cites this paper
• Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope

  2019cites this paper
• Management of metastatic prostate cancer: recent advances, clinical perspectives and future prospects

  2019cites this paper
• Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database

  2018cites this paper
• Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL

  2018cites this paper
• Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study

  2018cites this paper
• 2 nd generation anti-androgens and radiotherapy for localized prostate cancer

  2018cites this paper
• Long term response with abiraterone without lhrh analogs in metastatic castration resistant prostate cancer

  2017cites this paper
• Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer

  2017cites this paper
• Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts

  2017cites this paper
• Navigating the evolving therapeutic landscape in advanced prostate cancer.

  2017cites this paper
• A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer

  2016cites this paper
• Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: A systematic review of the literature.

  2016cites this paper
• QUINAZOLINE + BASED ! ALPHA 1 + ADRENOCEPTOR ! ANTAGONISTS ! AND ! PROSTATE ! CANCER !

  2016cites this paper
• Dramatic PSA Increase With Tumor Shrinkage After Initiating Degarelix in Advanced Prostate Cancer.

  2016cites this paper
• Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials

  2016cites this paper
• Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.

  2015cites this paper
• Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer

  2015cites this paper
• Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27)

  2015cites this paper
• Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study

  2015cites this paper
• Network analysis of an in vitro model of androgen-resistance in prostate cancer

  2015cites this paper
• Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry

  2015cites this paper
• Androgen receptor antagonists for prostate cancer therapy.

  2014cites this paper
• Managing advanced prostate cancer: the rapidly changing treatment landscape.

  2014cites this paper
• Novel agents in the management of castration resistant prostate cancer

  2014cites this paper
• The current abilities of third-generation luteinizing hormone-releasing hormone antagonists in the treatment of hormone-responsive prostate cancer

  2014cites this paper
• Effect of simvastatin on castration-resistant prostate cancer cells

  2014cites this paper
• Functional characterisation of phosphodiesterase 4D7 in prostate cancer

  2014cites this paper
• The hypothalamic–pituitary–gonadal axis and prostate cancer: implications for androgen deprivation therapy

  2014influential citation
• Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate‐risk, high‐risk, localized, and locally advanced prostate cancer

  2014cites this paper
• Long-Term Efficacy and Tolerability of Abdominal Once-Yearly Histrelin Acetate Subcutaneous Implants in Patients with Advanced Prostate Cancer

  2014cites this paper
• Современные возможности антагонистов лютеинизирующего гормона — рилизинг-гормона третьего поколения в лечении гормоночувствительного рака предстательной железы

  2014cites this paper
• Agonists of luteinizing hormone-releasing hormone in prostate cancer

  2013cites this paper
• An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer

  2013cites this paper
• Experience with degarelix in the treatment of prostate cancer

  2013cites this paper
• An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer

  2013cites this paper
• Progress in emerging therapies for advanced prostate cancer.

  2013cites this paper
• Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer

  2012cites this paper
• First-Line Hormonal Manipulation of Prostate Cancer

  2012cites this paper
• Risques prostatiques de la testostérone : nouveau retour du balancier?

  2012cites this paper
• Androgen deprivation therapy: past, present and future

  2012cites this paper
• Gonadotropin‐releasing hormone: An update review of the antagonists versus agonists

  2012cites this paper
• Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer.

  2012cites this paper
• Challenges in Diagnosis and Treatment of a Cervical Spinal Cord Injury Patient with Melanoma, Adenocarcinoma, and Hepatic and Osteolytic Metastases: Need to Implement Strategies for Prevention and Early Detection of Cancer in Spinal Cord Injury Patients

  2012cites this paper
• Effect of Concomitant Use of Flutamide and Luteinizing Hormone Releasing Hormone (LHRH) Analogue Versus Flutamide Alone on Pituitary Gonadotroph Cells of Adult Male Albino Rats

  2011cites this paper
• An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer

  2011cites this paper
• An investigation of cholesterol pathways in castration-resistant prostate cancer : the role of scavenger receptor class B type I (SR-BI)

  2011cites this paper
• Initial Flare Symptoms Resulting from Use of LHRH Agonist in Metastatic Prostate Cancer: Systematic Review and Economic Evaluation

  2011cites this paper
• Management of hormonal therapy for the treatment of advanced hormone-dependent prostate cancer: A pharmacoeconomics assessment of the use of Degarelix - Firmagon® compared to generic triptorelin

  2011cites this paper
• Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

  2011cites this paper
• Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?

  2010cites this paper
• Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.

  2010cites this paper
• Degarelix: a new hormonal treatment for prostate cancer

  2009cites this paper
• GnRH blockers: a changing paradigm in the management of prostate cancer

  2009cites this paper
• Leuprorelin depot injection: patient considerations in the management of prostatic cancer

  2008cites this paper
• Bicalutamide‐Associated Fulminant Hepatotoxicity

  2008cites this paper
• Pharmacological management of inappropriate sexual behaviours: a review of its evidence, rationale and scope in relation to men with intellectual disabilities.

  2008cites this paper
• The hazards of intermediate endpoints

  2007cites this paper
• The androgen receptor: a potential target for therapy of prostate cancer.

  2004cites this paper
• Cancer Management and Research Dovepress Six-month Gonadotropin Releasing Hormone (gnrh) Agonist Depots Provide Efficacy, Safety, Convenience, and Comfort

  year unknowncites this paper